tetano
Editor, Senior Moderator
Cureus
. 2023 Mar 28;15(3):e36809.
doi: 10.7759/cureus.36809. eCollection 2023 Mar.
Exploring the Potential of Broadly Neutralizing Antibodies for Treating SARS-CoV-2 Variants of Global Concern in 2023: A Comprehensive Clinical Review
Sai Dheeraj Gutlapalli[SUP] 1 [/SUP], Vijay Durga Pradeep Ganipineni[SUP] 2 3 [/SUP], Sumanth Danda[SUP] 4 [/SUP], Daniel Fabian[SUP] 1 [/SUP], Ikpechukwu J Okorie[SUP] 1 [/SUP], Jananthan Paramsothy[SUP] 1 [/SUP], Tharunjan Kailayanathan[SUP] 1 [/SUP], Rushaniya Umyarova[SUP] 1 [/SUP], Cinthya Aviles[SUP] 1 [/SUP], Sameer Krishna Prasad Garlapati[SUP] 5 [/SUP], Derek Ugwendum[SUP] 1 [/SUP], Jay Nfonoyim[SUP] 6 [/SUP]
Affiliations
Abstract
In the aftermath of the coronavirus disease 2019 (COVID-19) pandemic, the world is still seeing outbreaks of COVID-19 infections as of 2023, especially in populations that have been adequately vaccinated. This situation across the globe gives rise to important questions regarding the efficacy of current treatments and the real rate of mutations in the COVID-19 virus itself which can make the currently available treatments and vaccines obsolete. We have tried to answer a few of those questions and put forth some new questions of our own. Our efforts in this paper were directed towards understanding the utilization of broadly neutralizing antibodies as a treatment for COVID-19 infection with a particular focus on the Omicron variant and other newer variants. We gathered our data from three major databases: PubMed, Google Scholar, and Cochrane Central Register of Controlled Trials (CENTRAL). We have screened 7070 studies from inception till March 5, 2023, and gathered 63 articles that were relevant to the topic of interest. Based on the existing medical literature regarding the topic of interest and also based on our own personal and clinical experience treating COVID-19 patients across the multiple waves in the United States and India since the beginning of the pandemic, we have concluded that broad neutralizing antibodies could be an effective option for treatment and prophylaxis for current and future outbreaks of COVID-19 including the Omicron variant and newer variants. Further research, including clinical trials, is required to tailor optimal dosages, prevent adverse reactions/side effects, and develop treatment strategies.
Keywords: anti-sars-cov-2 antibodies; coronavirus disease 2019; covid-19 prophylaxis; intravenous immunoglobulin (ivig); omicron variant.
. 2023 Mar 28;15(3):e36809.
doi: 10.7759/cureus.36809. eCollection 2023 Mar.
Exploring the Potential of Broadly Neutralizing Antibodies for Treating SARS-CoV-2 Variants of Global Concern in 2023: A Comprehensive Clinical Review
Sai Dheeraj Gutlapalli[SUP] 1 [/SUP], Vijay Durga Pradeep Ganipineni[SUP] 2 3 [/SUP], Sumanth Danda[SUP] 4 [/SUP], Daniel Fabian[SUP] 1 [/SUP], Ikpechukwu J Okorie[SUP] 1 [/SUP], Jananthan Paramsothy[SUP] 1 [/SUP], Tharunjan Kailayanathan[SUP] 1 [/SUP], Rushaniya Umyarova[SUP] 1 [/SUP], Cinthya Aviles[SUP] 1 [/SUP], Sameer Krishna Prasad Garlapati[SUP] 5 [/SUP], Derek Ugwendum[SUP] 1 [/SUP], Jay Nfonoyim[SUP] 6 [/SUP]
Affiliations
- PMID: 37009363
- PMCID: PMC10060008
- DOI: 10.7759/cureus.36809
Abstract
In the aftermath of the coronavirus disease 2019 (COVID-19) pandemic, the world is still seeing outbreaks of COVID-19 infections as of 2023, especially in populations that have been adequately vaccinated. This situation across the globe gives rise to important questions regarding the efficacy of current treatments and the real rate of mutations in the COVID-19 virus itself which can make the currently available treatments and vaccines obsolete. We have tried to answer a few of those questions and put forth some new questions of our own. Our efforts in this paper were directed towards understanding the utilization of broadly neutralizing antibodies as a treatment for COVID-19 infection with a particular focus on the Omicron variant and other newer variants. We gathered our data from three major databases: PubMed, Google Scholar, and Cochrane Central Register of Controlled Trials (CENTRAL). We have screened 7070 studies from inception till March 5, 2023, and gathered 63 articles that were relevant to the topic of interest. Based on the existing medical literature regarding the topic of interest and also based on our own personal and clinical experience treating COVID-19 patients across the multiple waves in the United States and India since the beginning of the pandemic, we have concluded that broad neutralizing antibodies could be an effective option for treatment and prophylaxis for current and future outbreaks of COVID-19 including the Omicron variant and newer variants. Further research, including clinical trials, is required to tailor optimal dosages, prevent adverse reactions/side effects, and develop treatment strategies.
Keywords: anti-sars-cov-2 antibodies; coronavirus disease 2019; covid-19 prophylaxis; intravenous immunoglobulin (ivig); omicron variant.